Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?

Author(s): Michal Ciebiera, Salvatore G. Vitale*, Simone Ferrero, George A. Vilos, Fabio Barra, Salvatore Caruso, Antonio S. Laganà, Antoni Sierant, Antonio Cianci and Grzegorz Jakiel

Volume 26, Issue 3, 2020

Page: [300 - 309] Pages: 10

DOI: 10.2174/1381612826666200127092208

Price: $65

Abstract

Background: Vilaprisan (VPR) is a new orally available selective progesterone receptor modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively causes suppression of ovulation and inhibition of proliferation of endometrial, myometrial and UF cells.

Purpose: This review aims to summarize current knowledge on VPR from all studies, including clinical trials, conducted to date and to contextualize the potential role of VPR in future medical regimens for the treatment of UFs.

Methods: We performed a literature search in PubMed US National Library of Medicine and Google Scholar databases. Both databases were extensively searched for all original and review articles/book chapters as well as congress abstracts published in English until July 2019. The use of VPR for UF therapy was identified by using the keywords: “uterine fibroids” and “vilaprisan”.

Results: In phase I and II clinical trials, VPR was shown to be effective in ameliorating UF-related clinical symptoms, especially abnormal or excessive uterine bleeding and in shrinking UFs. The tolerability of VPR is roughly similar to that of ulipristal acetate (UPA) and it tends to be more favorable than that of GnRH-agonists.

Conclusion: Presently, all trials examining the utility of VPR for the treatment of UF are halted; likely, due to the recently reported cases of hepato-toxicity with UPA, in addition to non reassuring toxicology results from preclinical long-term testing on rodents, carried out in parallel with late stage testing on humans. An accurate summary of robust data related to the safety of VPR is urgently needed to draw definitive conclusions on the future clinical development of this drug for UF therapy.

Keywords: Vilaprisan, selective progesterone receptor modulator, uterine fibroid, leiomyoma, therapy, pharmacology.

« Previous Next »
[1]
Hervé F, Katty A, Isabelle Q, Céline S. Impact of uterine fibroids on quality of life: a national cross-sectional survey. Eur J Obstet Gynecol Reprod Biol 2018; 229: 32-7.
[http://dx.doi.org/10.1016/j.ejogrb.2018.07.032] [PMID: 30099225]
[2]
Laganà AS, Vergara D, Favilli A, et al. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease. Arch Gynecol Obstet 2017; 296(5): 855-67.
[http://dx.doi.org/10.1007/s00404-017-4515-5] [PMID: 28875276]
[3]
Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016; 22(6): 665-86.
[http://dx.doi.org/10.1093/humupd/dmw023] [PMID: 27466209]
[4]
Havryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid management: systematic review of the literature. JSLS 2017; 21(3) e2017.00041
[5]
Divakar H. Asymptomatic uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22(4): 643-54.
[http://dx.doi.org/10.1016/j.bpobgyn.2008.01.007] [PMID: 18375184]
[6]
Mas A, Tarazona M, Dasí Carrasco J, Estaca G, Cristóbal I, Monleón J. Updated approaches for management of uterine fibroids. Int J Womens Health 2017; 9: 607-17.
[http://dx.doi.org/10.2147/IJWH.S138982] [PMID: 28919823]
[7]
Sieroń D, Wiggermann P, Skupiński J, Kukawska-Sysio K, Lisek U, Koczy A. Uterine artery embolisation and magnetic resonance-guided focused ultrasound treatment of uterine fibroids. Pol J Radiol 2011; 76(2): 37-9.
[PMID: 22802829]
[8]
Donnez J, Donnez O, Courtoy GE, Dolmans MM. The place of selective progesterone receptor modulators in myoma therapy. Minerva Ginecol 2016; 68(3): 313-20.
[PMID: 26930390]
[9]
Faustino F, Martinho M, Reis J, Águas F. Update on medical treatment of uterine fibroids. Eur J Obstet Gynecol Reprod Biol 2017; 216: 61-8.
[http://dx.doi.org/10.1016/j.ejogrb.2017.06.047] [PMID: 28732252]
[10]
Singh SS, Belland L, Leyland N, von Riedemann S, Murji A. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol 2018; 218: 563-72. e1
[http://dx.doi.org/10.1016/j.ajog.2017.12.206]
[11]
Odejinmi F, Annan H, Mallick R. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids: an alternative perspective. Am J Obstet Gynecol 2018; 219(2): 211.
[http://dx.doi.org/10.1016/j.ajog.2018.03.029] [PMID: 29614277]
[12]
Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol 2012; 357(1-2): 18-29.
[http://dx.doi.org/10.1016/j.mce.2011.09.016] [PMID: 21952082]
[13]
Gogny A, Fiéni F. Aglepristone: a review on its clinical use in animals. Theriogenology 2016; 85(4): 555-66.
[http://dx.doi.org/10.1016/j.theriogenology.2015.10.010] [PMID: 26525399]
[14]
Deng L, Wu T, Chen XY, Xie L, Yang J. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2012; 10 CD005287
[http://dx.doi.org/10.1002/14651858.CD005287.pub4] [PMID: 23076912]
[15]
Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11(3): 293-307.
[http://dx.doi.org/10.1093/humupd/dmi002] [PMID: 15790602]
[16]
NCT00755755. PGL4001 Versus Placebo in uterine myomas (PEARLI) 2008.Available at:. clinicaltrials.govt/ct2/ show/NCT00755755
[17]
NCT00740831. PGL4001 Versus GnRH-agonist in uterine myomas (PEARLII) 2008.Available at:. clinicaltrails.gov/ ct2/NCT00740831
[18]
NCT01642472 PGL4001 efficacy assessment in reduction of symptoms due to uterine leiomyomata (PEARLext2) 2012.Avaialable at:. clinicaltrails.gov/ ct2/NCT01642472
[19]
NCT01156857. PGL4001 efficacy assessment in reduction of symptoms due to uterine leiomyomata (PEARLIII) 2010.Available at:. https://clinicaltrials.gov/ct2/show/NCT01156857
[20]
NCT01252069PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) 2010.Avaialable at:. https://clinicaltrials.gov/ ct2/show/NCT01252069
[21]
NCT01629563. PGL4001 efficacy assessment in reduction of symptoms due to uterine leiomyomata (PEARLIV) 2012.Avaialable at:. https://ichgcp.net/ de/ clinical-trials-registry/ NCT01629563
[22]
Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol 2018; 14(1): 107-16.
[http://dx.doi.org/10.1080/17425255.2018.1417389] [PMID: 29250979]
[23]
Donnez J, Donnez O, Dolmans MM. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil Steril 2014; 102(3): 640-8.
[http://dx.doi.org/10.1016/j.fertnstert.2014.06.041] [PMID: 25106762]
[24]
Ferrero S, Scala C, Vellone VG, et al. Preoperative treatment with ulipristal acetate before outpatient hysteroscopic myomectomy. Gynecol Obstet Invest 2020; 1-6. Online ahead of print.
[http://dx.doi.org/10.1159/000505604] [PMID: 31940645]
[25]
Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366(5): 421-32.
[http://dx.doi.org/10.1056/NEJMoa1103180] [PMID: 22296076]
[26]
Ciebiera M, Męczekalski B, Łukaszuk K, Jakiel G. Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy - 2 case studies. Gynecol Endocrinol 2019; 35(6): 473-7.
[http://dx.doi.org/10.1080/09513590.2018.1550062] [PMID: 30632825]
[27]
Bizzarri N, Ghirardi V, Remorgida V, Venturini PL, Ferrero S. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol 2015; 192: 22-6.
[http://dx.doi.org/10.1016/j.ejogrb.2015.06.018] [PMID: 26142912]
[28]
Ferrero S, Alessandri F, Vellone VG, Venturini PL, Leone Roberti Maggiore U. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 2016; 205: 43-7.
[http://dx.doi.org/10.1016/j.ejogrb.2016.08.021] [PMID: 27566221]
[29]
Ferrero S, Tafi E, Racca A, et al. Ulipristal acetate prior to high complexity hysteroscopic myomectomy: prospective study. J Minim Invasive Gynecol 2015; 22(6S): S181.
[http://dx.doi.org/10.1016/j.jmig.2015.08.666] [PMID: 27678974]
[30]
Fine PM. Ulipristal acetate: a new emergency contraceptive that is safe and more effective than levonorgestrel. Womens Health (Lond) 2011; 7(1): 9-17.
[http://dx.doi.org/10.2217/WHE.10.63] [PMID: 21175385]
[31]
Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care 2018; 23(1): 24-31.
[http://dx.doi.org/10.1080/13625187.2018.1433824] [PMID: 29436865]
[32]
Jatlaoui TC, Riley H, Curtis KM. Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception. Contraception 2016; 93(2): 93-112.
[http://dx.doi.org/10.1016/j.contraception.2015.11.001] [PMID: 26546020]
[33]
Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. Clinicoecon Outcomes Res 2015; 7: 213-25.
[http://dx.doi.org/10.2147/CEOR.S78115] [PMID: 25945062]
[34]
Odejinmi F, Oliver R, Mallick R. Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur? Womens Health (Lond) 2017; 13(3): 98-105.
[http://dx.doi.org/10.1177/1745505717740218] [PMID: 29105584]
[35]
Donnez J, Donnez O, Dolmans MM. The current place of medical therapy in uterine fibroid management. Best Pract Res Clin Obstet Gynaecol 2018; 46: 57-65.
[http://dx.doi.org/10.1016/j.bpobgyn.2017.10.008] [PMID: 29169896]
[36]
Donnez J, Courtoy GE, Dolmans MM. Fibroid management in premenopausal women. Climacteric 2019; 22(1): 27-33.
[http://dx.doi.org/10.1080/13697137.2018.1549216] [PMID: 30601065]
[37]
Geale K, Saridogan E, Lehmann M, Arriagada P, Hultberg M, Henriksson M. Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis. Clinicoecon Outcomes Res 2017; 9: 669-76.
[http://dx.doi.org/10.2147/CEOR.S143557] [PMID: 29138584]
[38]
Ferrero S, Scala C, Barra F. Regarding “Does ulipristal acetate affect surgical experience at laparoscopic myomectomy?”. J Minim Invasive Gynecol 2018; 25(3): 541.
[http://dx.doi.org/10.1016/j.jmig.2017.10.038] [PMID: 29175195]
[39]
Tafi E, Scala C, Leone Roberti Maggiore U, et al. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf 2015; 14(6): 965-77.
[http://dx.doi.org/10.1517/14740338.2015.1021773] [PMID: 25772793]
[40]
Kalampokas T, Kamath M, Boutas I, Kalampokas E. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol 2016; 32(2): 91-6.
[http://dx.doi.org/10.3109/09513590.2015.1106471] [PMID: 26572056]
[41]
Agency EM. Notification to the PRAC/EMA Secretariat of a Referral Under Article 20 of Regulation (EC) 726/2004 2017.
[42]
Agency EM. Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing 2018.
[43]
Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril 2018; 110(4): 593-5.
[http://dx.doi.org/10.1016/j.fertnstert.2018.06.044] [PMID: 30196943]
[44]
Agency EM. Esmya: new measures to minimise risk of rare but serious liver injury 2018.
[45]
Biospace.. FDA rejects allergan's uterine fibroid treatment following ema concerns over liver damage 2018.
[46]
Richter G. 12 months to December 2018 - Report to the Budapest Stock Exchange 2018.
[47]
Insight A. Vilaprisan - Bayer HealthCare Pharmaceuticals 2019.
[48]
National Center for Biotechnology Information. PubChem Database. Vilaprisan, CID=50915138 Available at:. https://pubchem.ncbi.nlm.nih.gov/compound/Vilaprisan
[49]
Barra FS M, Ferrero S Vilaprisan. Progesterone receptor modulator, Treatment of uterine fibroids. Drugs Future 2019; 44: 211.
[http://dx.doi.org/10.1358/dof.2019.44.3.2954360]
[50]
Möller C, Bone W, Cleve A, et al. Discovery of Vilaprisan (BAY 1002670): A highly potent and selective progesterone receptor modulator optimized for gynecologic therapies. ChemMedChem 2018; 13(21): 2271-80.
[http://dx.doi.org/10.1002/cmdc.201800487] [PMID: 30407750]
[51]
Wishart DS, Knox C, Guo AC, et al. a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34(Database issue): D668-72. 16381955
[52]
Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. Am J Obstet Gynecol 2015; 213(2): 141-60.
[http://dx.doi.org/10.1016/j.ajog.2015.03.019] [PMID: 25771213]
[53]
Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med 2017; 35(6): 473-80.
[http://dx.doi.org/10.1055/s-0037-1607264] [PMID: 29100234]
[54]
Vitale SG, Tropea A, Rossetti D, Carnelli M, Cianci A. Management of uterine leiomyomas in pregnancy: review of literature. Updates Surg 2013; 65(3): 179-82.
[http://dx.doi.org/10.1007/s13304-013-0198-z] [PMID: 23361218]
[55]
Vitale SG, Padula F, Gulino FA. Management of uterine fibroids in pregnancy: recent trends. Curr Opin Obstet Gynecol 2015; 27(6): 432-7.
[http://dx.doi.org/10.1097/GCO.0000000000000220] [PMID: 26485457]
[56]
Vitagliano A, Noventa M, Di Spiezio Sardo A, et al. Uterine fibroid size modifications during pregnancy and puerperium: evidence from the first systematic review of literature. Arch Gynecol Obstet 2018; 297(4): 823-35.
[http://dx.doi.org/10.1007/s00404-017-4621-4] [PMID: 29236171]
[57]
Marsh EE, Chibber S, Saad W. Patient-centered care and uterine fibroids. Semin Reprod Med 2017; 35(6): 560-4.
[http://dx.doi.org/10.1055/s-0037-1607267] [PMID: 29100243]
[58]
Stewart EA, Lytle BL, Thomas L, et al. The comparing options for management: patient-centered results for uterine fibroids (compareuf) registry: rationale and design. Am J Obstet Gynecol 2018; 219: 95: e1-95. e10
[59]
Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med 2015; 372(17): 1646-55.
[http://dx.doi.org/10.1056/NEJMcp1411029] [PMID: 25901428]
[60]
Vitale SG. The Biopsy Snake Grasper Sec. VITALE: a new tool for office hysteroscopy. J Minim Invasive Gynecol 2019. In press
[http://dx.doi.org/10.1016/j.jmig.2019.12.014] [PMID: 31884079.]
[61]
Laughlin-Tommaso S, Barnard EP. FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. Am J Obstet Gynecol 2019; 220: 174 e1-174 e13.
[62]
Filipowska J, Loziński T. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) in treatment of symptomatic uterine myomas. Pol J Radiol 2014; 79: 439-43.
[http://dx.doi.org/10.12659/PJR.890606] [PMID: 25469176]
[63]
Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012; 206: 211. e1-9.
[http://dx.doi.org/10.1016/j.ajog.2011.12.002]
[64]
Wu HY, Wang KC. Minimally invasive approaches to the surgical management of fibroids. Semin Reprod Med 2017; 35(6): 533-48.
[http://dx.doi.org/10.1055/s-0037-1606304] [PMID: 29100241]
[65]
Vitale SG, Sapia F, Rapisarda AMC, et al. Hysteroscopic morcellation of submucous myomas: a systematic review. BioMed Res Int 2017; 2017 6848250
[http://dx.doi.org/10.1155/2017/6848250] [PMID: 28948169]
[66]
Laganà AS, Vitale SG, Muscia V, et al. Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review. Arch Gynecol Obstet 2017; 295(3): 661-7.
[http://dx.doi.org/10.1007/s00404-016-4244-1] [PMID: 27904953]
[67]
West CP, Lumsden MA, Lawson S, Williamson J, Baird DT. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48(1): 45-51.
[http://dx.doi.org/10.1016/S0015-0282(16)59288-7] [PMID: 2954863]
[68]
Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev 2017; 11 CD000547
[http://dx.doi.org/10.1002/14651858.CD000547.pub2] [PMID: 29139105]
[69]
Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond) 2015; 11(1): 19-28.
[http://dx.doi.org/10.2217/WHE.14.68] [PMID: 25581052]
[70]
Ciebiera M, Łukaszuk K, Męczekalski B, et al. Alternative oral agents in prophylaxis and therapy of uterine fibroids-an up-to-date review. Int J Mol Sci 2017; 18(12): 18.
[http://dx.doi.org/10.3390/ijms18122586] [PMID: 29194370]
[71]
Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc) 2019; 55(4): 237-46.
[http://dx.doi.org/10.1358/dot.2019.55.4.2930713] [PMID: 31050692]
[72]
Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab 2017; 102(5): 1683-91.
[http://dx.doi.org/10.1210/jc.2016-3845] [PMID: 28323948]
[73]
Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril 2017; 108: 152-60. e4
[74]
Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol 2013; 171(2): 329-32.
[http://dx.doi.org/10.1016/j.ejogrb.2013.09.010] [PMID: 24103533]
[75]
Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev 2013; (10): CD009505
[PMID: 24151065]
[76]
Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod 2013; 28(8): 2253-64.
[http://dx.doi.org/10.1093/humrep/det247] [PMID: 23739217]
[77]
Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs 2018; 27(5): 497-505.
[http://dx.doi.org/10.1080/13543784.2018.1471134] [PMID: 29718788]
[78]
Schütt B, Kaiser A, Schultze-Mosgau MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 2016; 31(8): 1703-12.
[http://dx.doi.org/10.1093/humrep/dew140] [PMID: 27288475]
[79]
Courtoy GE, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015; 104: 426-34. e1.
[http://dx.doi.org/10.1016/j.fertnstert.2015.04.025]
[80]
Courtoy GE, Henriet P, Marbaix E, et al. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metab 2018; 103(4): 1566-73.
[http://dx.doi.org/10.1210/jc.2017-02295] [PMID: 29408988]
[81]
Ciebiera M, Wlodarczyk M, Wrzosek M, Slabuszewska-Jozwiak A, Nowicka G, Jakiel G. Ulipristal acetate decreases transforming growth factor beta3 serum and tumor tissue concentrations in patients with uterine fibroids. Fertil Steril 2018; 109: 501-7. e2.
[82]
Schultze-Mosgau MH, Höchel J, Prien O, et al. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet 2018; 57(8): 1001-15.
[http://dx.doi.org/10.1007/s40262-017-0607-4] [PMID: 29330782]
[83]
Schultze-Mosgau MH, Schuett B, Hafner FT, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther 2017; 55(1): 16-24.
[http://dx.doi.org/10.5414/CP202756] [PMID: 27841155]
[84]
NCT02456129. Medicine USNLo Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan 2015.Avaialable at:. https://ichgcp.net/ clinicaltrials- registry/ NCT02456129/
[85]
NCT02262663. Medicine USNLo Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan 2014.Avaialable at:. https://clinicaltrials.gov/ct2/show/NCT032262663
[86]
NCT03210246. Medicine USNLo Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC 2017.Avaialable at:. https://clinicaltrials.gov/ct2/show/NCT03210246
[87]
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670 2013.NCT01816815..
[88]
Bradley LD, Singh SS, Simon J, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril 2019; 111(2): 240-8.
[http://dx.doi.org/10.1016/j.fertnstert.2018.10.012] [PMID: 30527839]
[89]
NCT02131662. Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap (ASTEROID 1) 2014.Available at:. https://clinicaltrials.gov/ct2/show/NCT02131662
[90]
NCT03092999. Medicine USNLo Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan) 2017.Available at:. https://clinicaltrials.gov/ ct2/show/results/ NCT03092999
[91]
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646-9.
[http://dx.doi.org/10.1002/bjs.1800600817] [PMID: 4541913]
[92]
Chattopadhyay N, Riecke K, Ligges S, Zimmermann T, Halabi A, Schultze-Mosgau MH. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: an open-label, single-dose, parallel-group study. Br J Clin Pharmacol 2019; 85(9): 2011-21.
[http://dx.doi.org/10.1111/bcp.13992] [PMID: 31112623]
[93]
NCT03342859. Medicine USNLo Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned 2017.Available at:. https://clinicaltrials.gov/ ct2/ show/ NCT03342859
[94]
NCT02465814. Medicine USNLo Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids (ASTEROID 2) 2015.Available at:. https://clinicaltrials.gov/ct2/show/NCT02465814
[95]
Seitz C, Bumbuliene Ž, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials 2017; 55: 56-62.
[http://dx.doi.org/10.1016/j.cct.2017.02.002] [PMID: 28185997]
[96]
NCT03400943. Medicine USNLo Assess safety and efficacy of vilaprisan in subjects with uterine fibroids (ASTEROID 3) 2018.Available at:. https://clinicaltrials.gov/ct2/show/ NCT03400943
[97]
NCT03400956. Medicine USNLo Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) 2018.Available at:. https://clinicaltrials.gov/ct2/show/ NCT03400956
[98]
NCT03699176. Medicine USNLo Assessment of safety and efficacy of vilaprisan in subjects with uterine fibroids (ASTEROID 7) 2018.Available at:. https://clinicaltrials.gov/ ct2/ show/ NCT03699176
[99]
NCT03194646. A Study to assess the safety and efficacy of vilaprisan in japanese subjects with uterine fibroids and heavy menstrual bleeding (ASTEROID 8) 2018.Available at:. https:// clinicaltrials.gov/ct2/show/ NCT03194646
[100]
NCT03240523. Medicine USNLo Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 5) 2017.Available at:. https://clinicaltrials.gov/ct2/show/ NCT03240523
[101]
NCT03194646. Medicine USNLo Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 6) 2017.Available at:. https://clinicaltrials.gov/ct2/show/NCT03194646
[102]
Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs 2018; 27(5): 445-58.
[http://dx.doi.org/10.1080/13543784.2018.1471135] [PMID: 29708812]
[103]
Barra F, Romano A, Grandi G, Facchinetti F, Ferrero S. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. Expert Opin Investig Drugs 2019; 28(6): 501-4.
[http://dx.doi.org/10.1080/13543784.2019.1618269] [PMID: 31072144]
[104]
van der Burg B, van der Saag PT. Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Mol Hum Reprod 1996; 2(6): 433-8.
[http://dx.doi.org/10.1093/molehr/2.6.433] [PMID: 9238713]
[105]
Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol 2008; 583(2-3): 322-39.
[http://dx.doi.org/10.1016/j.ejphar.2007.12.033] [PMID: 18295199]
[106]
NCT03573336. Medicine USNLo Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis (VILLENDO) 2018.Available at:. https://clinicaltrials.gov/ct2/show/NCT03573336
[107]
Schütt B, Schultze-Mosgau MH, Draeger C, et al. Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women. J Clin Pharmacol 2018; 58(2): 228-39.
[http://dx.doi.org/10.1002/jcph.998] [PMID: 28940451]
[108]
Kalgutkar AS. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs. Curr Med Chem 2015; 22(4): 438-64.
[http://dx.doi.org/10.2174/0929867321666141112122118] [PMID: 25388012]
[109]
Chattopadhyay N, Kanacher T, Casjens M, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol 2018; 84(12): 2857-66.
[http://dx.doi.org/10.1111/bcp.13750] [PMID: 30171692]
[110]
Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21(5): 591-8.
[http://dx.doi.org/10.1038/modpathol.2008.19] [PMID: 18246050]
[111]
De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol 2017; 214: 56-64.
[http://dx.doi.org/10.1016/j.ejogrb.2017.04.042] [PMID: 28482329]
[112]
Annual Report 2018. Bayer Pharmaceuticals [cited 2020 Jan 9] Available from:. (https://www.bayer.com/en/bayer-annual-report- 2018.pdfx)
[113]
Reuters.. Bayer halts vilaprisan drug trials due to toxicology data 2018.
[114]
Stewart EA, Diamond MP, Williams ARW, et al. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Hum Reprod 2019; 34(4): 623-34.
[http://dx.doi.org/10.1093/humrep/dez007] [PMID: 30865281]
[115]
Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther 2019; 19(4): 343-60.
[http://dx.doi.org/10.1080/14712598.2019.1581761] [PMID: 30763525]
[116]
Laganà AS, Vitale SG, Granese R, et al. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol 2017; 13(6): 593-6.
[http://dx.doi.org/10.1080/17425255.2017.1297421] [PMID: 28537213]

Rights & Permissions Print Cite
Article Metrics
34
4
© 2024 Bentham Science Publishers | Privacy Policy